AAPS Gateway 2012: Vetter - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

AAPS Gateway 2012: Vetter


In Europe, contact:
Vetter Pharma International GmbH
Eywiesenstrasse 5
88212 Ravensburg, Germany
Phone: +49 (0)751 3700-0
info@vetter-pharma.com

In the U.S., contact:
Vetter Pharma International USA Inc.
Illinois Science + Technology Park
4901 Searle Parkway, Suite 300A
Skokie, IL 60077
USA
Phone: 847.581.6888
infoUS@vetter-pharma.com

Vetter is a leading contract development and manufacturing organization (CDMO) that specializes in the aseptic filling of syringes, cartridges and vials. The company has extensive experience with biologics and other complex compounds, including monoclonal antibodies, peptides, interferons and vaccines. Collaborating with pharma/biotech clients worldwide, Vetter supports products from preclinical development through global market supply. The company offers state-of-the-art technology and innovative processes to promote product quality and maximize API yield. Vetter’s Chicago facility, an expansion of Vetter Development Service, manufactures early-stage clinical products, with seamless transfer at Phase III to Vetter’s commercial manufacturing facilities.

Vetter now offers expanded clinical development services in US and Europe! Learn more at AAPS Annual Meeting 2012 in Chicago at Booth #5020.

 

Vetter Corporate Brochure

Vetter Development Service Brochure

Vetter Packaging Solutions Brochure

Press release: Vetter expands its capacities and services for prefilled syringes

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
20%
To all process for new products only
13%
To select process for new products only
25%
To select processes for both new and legacy products
20%
Do not use QbD
23%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
Overcoming the Challenges in Biopharmaceutical Stability Testing
PhRMA Dismayed by Special 301 Report
FindPharma Custom Search

Click here